Zealand Pharma A/S
ZEAL
Classement en actions
#5528
Zealand Pharma A/S is a Danish biotechnology firm dedicated to the... Zealand Pharma A/S is a Danish biotechnology firm dedicated to the identification, progression, and market introduction of peptide-based therapeutics. The company concentrates its efforts on treatments for gastrointestinal and metabolic ailments, as well as other specialized conditions where current medical options are insufficient. Its commercialized product, Dasiglucagon, is an injectable solution provided in a pre-filled syringe or autoinjector, used to address severe hypoglycemia. Furthermore, Zealand Pharma is actively developing Dasiglucagon for inclusion in bi-hormone artificial pancreas systems that integrate both insulin and dasiglucagon. The compound Dasiglucagon is also undergoing late-stage (Phase III) clinical trials for congenital hyperinsulinism. Another significant asset in its development pipeline is glepaglutide, a long-acting GLP-2 analog, which is likewise in Phase III clinical studies for treating short bowel syndrome. Founded in 1998 and headquartered in Copenhagen, Denmark, Zealand Pharma A/S maintains strategic alliances with a range of partners, including Sanofi-Aventis Deutschland GmbH, Boehringer Ingelheim International GmbH, Alexion Pharmaceuticals, Inc., and Beta Bionics, Inc.
Prix de l'action
$34.57
Capitalisation boursière
$2.40B
Changement (1 jour)
-0.99%
Changement (1 an)
-52.22%
Pays
DK
Échange Zealand Pharma A/S (ZEAL)
Catégorie
Healthcare
Historique du prix de l'action pour Zealand Pharma A/S (ZEAL)
Prix de clôture le plus élevé : $36.07 le 2026-10-01
Prix de clôture le plus bas : $14.13 le 2013-02-01
Prix de clôture le plus bas : $14.13 le 2013-02-01
Historique du prix de l'action de Zealand Pharma A/S de 2013 à 2026
Performance annuelle du prix de l'action
| Année | Performance |
|---|---|
| 2026 (TTM) | -28.90% |
| 2025 | -27.05% |
| 2024 | 103.83% |
| 2023 | 83.97% |
| 2022 | 12.44% |
| 2021 | -30.48% |
| 2020 | 12.58% |
| 2019 | 163.90% |
| 2018 | -13.34% |
| 2017 | -14.27% |
| 2016 | -23.32% |
| 2015 | 66.31% |
| 2014 | 25.21% |
| 2013 | 0.00% |
Prix de l'action pour des entreprises similaires ou concurrentes
| Entreprise | Prix de l'action | Variation 1a% | Pays |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $760.15 | 8.04% |
CH
|
